MA28786B1 - Antagonistes multivalents de l'antigene vla-4 comportant des fractions polymeres - Google Patents
Antagonistes multivalents de l'antigene vla-4 comportant des fractions polymeresInfo
- Publication number
- MA28786B1 MA28786B1 MA29658A MA29658A MA28786B1 MA 28786 B1 MA28786 B1 MA 28786B1 MA 29658 A MA29658 A MA 29658A MA 29658 A MA29658 A MA 29658A MA 28786 B1 MA28786 B1 MA 28786B1
- Authority
- MA
- Morocco
- Prior art keywords
- vla
- conjugates
- antigen
- inflammatory
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
Abstract
Sont révélés les conjugués qui lient le VLA-4. Certains de ces conjugués inhibent aussi l'adhésion de leucocyte et, en particulier, l'adhésion de leucocyte initié par VLA-4. Tels conjugués sont utiles dans le traitement des maladies inflammatoires chez un patient mammifère, par exmeple, human, tel que l'ashme, maladie d'Alzheimer, athérosclérose, démence due au SIDA, diabètes, l'affection abdominale inflammatoire, la polyarthrite rhumatoïde, la greffe de tissu, métastase de tumeur et ischémie myocardique. Le conjugués peuvent être administrés aussi pour le traitement des maladies inflammatoires de cerveau tel que la sclérose en plaque.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58697504P | 2004-07-08 | 2004-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28786B1 true MA28786B1 (fr) | 2007-08-01 |
Family
ID=35501261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29658A MA28786B1 (fr) | 2004-07-08 | 2007-02-05 | Antagonistes multivalents de l'antigene vla-4 comportant des fractions polymeres |
Country Status (20)
Country | Link |
---|---|
US (4) | US7794700B2 (fr) |
EP (4) | EP2258400A3 (fr) |
JP (1) | JP2008505927A (fr) |
KR (1) | KR101273614B1 (fr) |
CN (1) | CN101035563B (fr) |
AR (1) | AR050425A1 (fr) |
AU (1) | AU2005265316B2 (fr) |
BR (1) | BRPI0513143A (fr) |
CA (1) | CA2573245C (fr) |
EA (1) | EA012433B1 (fr) |
EC (1) | ECSP077231A (fr) |
HK (1) | HK1111674A1 (fr) |
IL (1) | IL180558A0 (fr) |
MA (1) | MA28786B1 (fr) |
MX (1) | MX2007000228A (fr) |
NO (1) | NO20070216L (fr) |
NZ (1) | NZ588839A (fr) |
TW (1) | TWI418346B (fr) |
WO (1) | WO2006010054A2 (fr) |
ZA (1) | ZA200700238B (fr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1144384B1 (fr) * | 1999-01-22 | 2007-10-31 | Elan Pharmaceuticals, Inc. | Composes inhibant l'adhesion aux leucocytes a mediation assuree par vla-4 |
US7595318B2 (en) * | 2004-01-23 | 2009-09-29 | Elan Pharmaceuticals, Inc. | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
TWI418346B (zh) | 2004-07-08 | 2013-12-11 | Elan Pharm Inc | 包括聚合物部分之多價vla-4拮抗劑 |
US8030328B2 (en) * | 2005-05-20 | 2011-10-04 | Elan Pharmaceuticals, Inc. | Imidazolone phenylalanine derivatives |
KR20080031053A (ko) * | 2005-07-08 | 2008-04-07 | 엘란 파마슈티칼스, 인크. | 치료, 농업 및 식품 첨가제 화합물의 중합체 컨쥬게이트의제조 방법 |
DK1940826T3 (da) * | 2005-09-29 | 2011-04-18 | Elan Pharm Inc | Pyrimidinylamidforbindelser, der inhiberer leukocytadhæsion medieret gennem BLA-4 |
WO2007041324A1 (fr) * | 2005-09-29 | 2007-04-12 | Elan Pharmaceuticals, Inc. | Composes de pyrimidinyl amide qui inhibent l'adherence leucocytaire a mediation par vla-4 |
US20090111828A1 (en) * | 2005-11-23 | 2009-04-30 | Astrazeneca Ab | L-alanine derivatives |
NZ570679A (en) * | 2006-02-27 | 2011-01-28 | Elan Pharm Inc | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated By VLA-4 |
CA2641513C (fr) * | 2006-02-28 | 2021-09-21 | Elan Pharmaceuticals, Inc. | Methodes pour traiter des maladies inflammatoires et auto-immunes avec du natalizumab |
JP2009531304A (ja) * | 2006-02-28 | 2009-09-03 | エラン ファーマシューティカルズ,インコーポレイテッド | α−4阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法 |
SG170058A1 (en) * | 2006-03-03 | 2011-04-29 | Elan Pharm Inc | Methods of treating inflammatory and autoimmune diseases with natalizumab |
JP2009538338A (ja) | 2006-05-22 | 2009-11-05 | イーラン ファーマスーティカルズ、インコーポレイテッド | 治療用、農業用及び食品添加用化合物のポリマー複合体の調製 |
EP2049490A1 (fr) * | 2006-06-09 | 2009-04-22 | Astra Zeneca AB | Dérivés de n-(benzoyl)-o-[2-(pyridin-2-ylamino)ethyl]-l-tyrosine et composés similaires en tant que antagonists de a5b1 pour le traitement de tumeurs solides |
US20090062267A1 (en) * | 2007-01-29 | 2009-03-05 | Astrazeneca Ab | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS |
US20100150915A1 (en) | 2007-02-20 | 2010-06-17 | Stewart Edward J | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
WO2008125811A1 (fr) * | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | DÉRIVÉS DE N-[HÉTÉROARYLCARBONYL]-S-THIÉNYL-L-ALANINE EN TANT QU'ANTAGONISTES DE L'INTÉGRINE α5β1 |
WO2008153967A1 (fr) * | 2007-06-08 | 2008-12-18 | Contec Therapeutics, Inc. | Conjugués antagonistes de bk1 |
JP2011506322A (ja) * | 2007-12-07 | 2011-03-03 | エラン ファーマシューティカルズ,インコーポレイテッド | 液性腫瘍を治療するための方法および組成物 |
EP2085407A1 (fr) | 2008-02-04 | 2009-08-05 | Sahltech I Göteborg AB | Traitement de purpura thrombopénique idiopathique |
CA2760151A1 (fr) * | 2009-04-27 | 2010-11-04 | Elan Pharmaceuticals, Inc. | Antagonistes a base de pyridinone d'integrines alpha-4 |
US20120258093A1 (en) * | 2009-08-20 | 2012-10-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
EP2524060B1 (fr) | 2010-01-11 | 2017-11-29 | Biogen MA Inc. | Essai d'anticorps anti-virus jc |
US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
US9561285B2 (en) * | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
EA201201482A1 (ru) * | 2010-04-30 | 2013-03-29 | Элан Фармасьютикалз, Инк. | Селективные ингибиторы интегрина |
ES2729945T3 (es) | 2011-05-31 | 2019-11-07 | Biogen Ma Inc | Procedimiento para valorar el riesgo de LMP |
WO2013019326A2 (fr) * | 2011-08-03 | 2013-02-07 | Henkel Corporation | Adhésif structurel électroconducteur |
JP6343600B2 (ja) | 2013-02-28 | 2018-06-13 | 武田薬品工業株式会社 | スルホニルクロライド化合物の製造法 |
WO2014193804A1 (fr) | 2013-05-28 | 2014-12-04 | Biogen Idec Ma Inc. | Méthodes d'évaluation de risque de développement d'une lemp |
JP2016523931A (ja) * | 2013-07-05 | 2016-08-12 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 脳卒中治療のための組成物及び方法 |
WO2015123447A1 (fr) * | 2014-02-12 | 2015-08-20 | 7 Hills Pharma, Llc | Compositions et procédés d'amélioration de la nostocytose et la prise de greffe de cellules souches hématopoïétiques |
US20200255530A1 (en) * | 2015-07-23 | 2020-08-13 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
WO2020092383A1 (fr) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Composés pour l'inhibition de l'intégrine alpha 4 bêta 7 |
AU2019373245C1 (en) | 2018-10-30 | 2022-10-27 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4β7 integrin |
EP3873900A1 (fr) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Dérivés d'imidazopyridine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7 |
CN112969687B (zh) | 2018-10-30 | 2024-08-23 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
WO2021030438A1 (fr) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Composés pour l'inhibition de l'intégrine alpha 4 bêta 7 |
WO2024054632A2 (fr) * | 2022-09-08 | 2024-03-14 | Roswell ME Inc. | Conjugaison multifonctionnelle n-terminale de protéines et de peptides pour la biodétection |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US5177059A (en) | 1989-11-15 | 1993-01-05 | Sandoz Ltd. | Polymyxin B conjugates |
DE4107857A1 (de) | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
JPH06506217A (ja) | 1991-03-18 | 1994-07-14 | エンゾン,インコーポレーテッド | ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体 |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
EP1017382B1 (fr) | 1997-05-29 | 2006-03-01 | Merck & Co., Inc. (a New Jersey corp.) | Acide biarylalcanoique utilise en tant qu'inhibiteur de l'adhesion cellulaire |
JP2002512625A (ja) * | 1997-05-29 | 2002-04-23 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としての複素環アミド化合物 |
AR016133A1 (es) | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
US6489300B1 (en) | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6939855B2 (en) | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
DK1411075T3 (da) | 1998-03-12 | 2008-10-27 | Nektar Therapeutics Al Corp | Fremgangsmåde til fremstilling af polymerkonjugater |
GB9821061D0 (en) * | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
WO2000043372A1 (fr) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Derives d'acyle utiles pour traiter des affections associees a vla-4 |
EP1144384B1 (fr) | 1999-01-22 | 2007-10-31 | Elan Pharmaceuticals, Inc. | Composes inhibant l'adhesion aux leucocytes a mediation assuree par vla-4 |
US6436904B1 (en) | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
CZ2002518A3 (cs) * | 1999-08-13 | 2002-05-15 | Biogen, Inc. | Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují |
WO2001054690A1 (fr) * | 2000-01-28 | 2001-08-02 | Biogen, Inc. | Compositions pharmaceutiques contenant des composes d'integrine anti-beta 1 et utilisations correspondantes |
US6803370B2 (en) | 2000-07-21 | 2004-10-12 | Elan Pharmaceuticals, Inc. | Alpha amino acid derivatives—inhibitors of leukocyte adhesion mediated by VLA-4 |
US20040043030A1 (en) | 2001-07-31 | 2004-03-04 | Immunomedics, Inc. | Polymeric delivery systems |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
ES2197003B1 (es) * | 2002-04-08 | 2005-03-16 | J. URIACH & CIA S.A. | Nuevos compuestos antagonistas de integrinas alfa. |
TW200307671A (en) * | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
KR101260497B1 (ko) | 2003-01-24 | 2013-09-12 | 엘란 파마슈티칼스, 인크. | 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료 및 조성물 |
JP2007524626A (ja) * | 2003-06-25 | 2007-08-30 | エラン ファーマシューティカルズ,インコーポレイテッド | 関節リウマチを治療する方法および組成物 |
US7595318B2 (en) | 2004-01-23 | 2009-09-29 | Elan Pharmaceuticals, Inc. | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
JP2007531735A (ja) | 2004-04-01 | 2007-11-08 | エラン ファーマシューティカルズ,インコーポレイテッド | ステロイド節約剤および該節約剤を使用する方法 |
WO2005111020A2 (fr) * | 2004-04-30 | 2005-11-24 | Elan Pharmaceuticals, Inc. | Analogues d’hydantoïne de pyrimidine qui empêchent l’adhésion des leucocytes par l’intermédiaire de vla-4 |
TWI418346B (zh) * | 2004-07-08 | 2013-12-11 | Elan Pharm Inc | 包括聚合物部分之多價vla-4拮抗劑 |
US8030328B2 (en) | 2005-05-20 | 2011-10-04 | Elan Pharmaceuticals, Inc. | Imidazolone phenylalanine derivatives |
KR20080031053A (ko) | 2005-07-08 | 2008-04-07 | 엘란 파마슈티칼스, 인크. | 치료, 농업 및 식품 첨가제 화합물의 중합체 컨쥬게이트의제조 방법 |
JP2011506322A (ja) | 2007-12-07 | 2011-03-03 | エラン ファーマシューティカルズ,インコーポレイテッド | 液性腫瘍を治療するための方法および組成物 |
-
2005
- 2005-07-08 TW TW094123303A patent/TWI418346B/zh not_active IP Right Cessation
- 2005-07-08 AU AU2005265316A patent/AU2005265316B2/en not_active Ceased
- 2005-07-08 CA CA2573245A patent/CA2573245C/fr not_active Expired - Fee Related
- 2005-07-08 EP EP10180274A patent/EP2258400A3/fr not_active Withdrawn
- 2005-07-08 CN CN2005800298537A patent/CN101035563B/zh not_active Expired - Fee Related
- 2005-07-08 US US11/177,748 patent/US7794700B2/en not_active Expired - Fee Related
- 2005-07-08 NZ NZ588839A patent/NZ588839A/xx not_active IP Right Cessation
- 2005-07-08 KR KR1020077003108A patent/KR101273614B1/ko not_active IP Right Cessation
- 2005-07-08 EP EP05770402A patent/EP1765412A2/fr not_active Withdrawn
- 2005-07-08 WO PCT/US2005/024369 patent/WO2006010054A2/fr active Application Filing
- 2005-07-08 JP JP2007520561A patent/JP2008505927A/ja active Pending
- 2005-07-08 BR BRPI0513143-0A patent/BRPI0513143A/pt not_active IP Right Cessation
- 2005-07-08 EA EA200700212A patent/EA012433B1/ru not_active IP Right Cessation
- 2005-07-08 AR ARP050102848A patent/AR050425A1/es not_active Application Discontinuation
- 2005-07-08 MX MX2007000228A patent/MX2007000228A/es active IP Right Grant
- 2005-07-08 EP EP10179709A patent/EP2258399A3/fr not_active Withdrawn
- 2005-07-08 EP EP10179711A patent/EP2298356A3/fr not_active Withdrawn
-
2007
- 2007-01-04 IL IL180558A patent/IL180558A0/en unknown
- 2007-01-09 ZA ZA200700238A patent/ZA200700238B/en unknown
- 2007-01-12 NO NO20070216A patent/NO20070216L/no not_active Application Discontinuation
- 2007-02-05 MA MA29658A patent/MA28786B1/fr unknown
- 2007-02-08 EC EC2007007231A patent/ECSP077231A/es unknown
-
2008
- 2008-02-29 HK HK08102319.2A patent/HK1111674A1/xx not_active IP Right Cessation
-
2010
- 2010-09-08 US US12/877,496 patent/US8263063B2/en not_active Expired - Fee Related
-
2012
- 2012-09-07 US US13/606,783 patent/US20120329807A1/en not_active Abandoned
-
2013
- 2013-03-15 US US13/831,625 patent/US20130338164A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28786B1 (fr) | Antagonistes multivalents de l'antigene vla-4 comportant des fractions polymeres | |
MA30318B1 (fr) | Composes de sulfonamide de pyrimidinyle inhibant l'adhesion leucocytaire mediee par vla-4 | |
NO963280L (no) | Anvendelse av anti-TNF antistoffer som legemidler i behandling av sykdommer som involverer forhöyede interleukin-6 serumnivåer | |
WO2006002177A3 (fr) | Anticorps anti-recepteur aux interferons alpha 1 et leurs utilisations | |
SG155186A1 (en) | Il-17 antagonistic antibodies | |
WO2010055366A3 (fr) | Anticorps monoclonaux anti-il-21 humain | |
HK1072608A1 (en) | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | |
EP2371862A3 (fr) | Compositions monovalentes pour la liaison au CD40L et procédés d'utilisation | |
EA200401561A1 (ru) | Гетероарильные соединения, которые ингибируют опосредованную 4-интегринами адгезию лейкоцитов | |
DK1940826T3 (da) | Pyrimidinylamidforbindelser, der inhiberer leukocytadhæsion medieret gennem BLA-4 | |
ATE502031T1 (de) | Carbamatverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren | |
ATE339205T1 (de) | (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen | |
ATE264298T1 (de) | Alpha-aminoessigsäure derivate als alpha 4 beta 7-rezeptor antagonisten | |
MA30665B1 (fr) | Traitement de maladies rhumatoïdes avec des glucocorticoïdes a liberation retardee. | |
WO2002008201A3 (fr) | Derives de l'acide beta-amino inhibiteurs de l'adhesion des leucocytes induite par vla-4 | |
NO20026286D0 (no) | Nye peptider | |
WO2004058803A3 (fr) | Nouveaux peptides | |
WO2002098454A3 (fr) | Molecules recombinees a immunogenicite reduite, procedes et produits intermediaires pour les obtenir et leur utilisation dans des compositions pharmaceutiques et des outils diagnostiques | |
ATE224730T1 (de) | Mittel zur behandlung von pigmentierungsstörungen |